Engı̇n Ulukaya

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Didem Karakaş · 2 shared papers, 2023–2025 · strength 0.46
   • Paper eEF2K is a poor prognostic factor and novel molecular target in pancreatic cancer: regulating tumor growth and progress… DOI 10.1038/s41419-025-07803-w↗
   • Paper Targeting Periostin Expression Makes Pancreatic Cancer Spheroids More Vulnerable to Natural Killer Cells. DOI 10.3390/biomedicines11020270↗
2. Soykan Ağar · 1 shared paper, 2023 · strength 0.31
   • Paper The Inhibition Mechanism of Pancreatic Ductal Adenocarcinoma via LXR Receptors: A Multifaceted Approach Integrating Mol… DOI 10.31557/apjcp.2023.24.12.4103↗
3. Ahmed Amine Ashour · 1 shared paper, 2025 · strength 0.24
   • Paper eEF2K is a poor prognostic factor and novel molecular target in pancreatic cancer: regulating tumor growth and progress… DOI 10.1038/s41419-025-07803-w↗
4. Bülent Özpolat · 1 shared paper, 2025 · strength 0.24
   • Paper eEF2K is a poor prognostic factor and novel molecular target in pancreatic cancer: regulating tumor growth and progress… DOI 10.1038/s41419-025-07803-w↗
5. Dimitrios E. Magouliotis · 1 shared paper, 2018 · strength 0.08
   • Paper Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: emerging allies in the war on a devas… DOI 10.1016/j.jprot.2018.01.012↗
6. Konstantinos S. Dimas · 1 shared paper, 2018 · strength 0.08
   • Paper Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: emerging allies in the war on a devas… DOI 10.1016/j.jprot.2018.01.012↗
7. Evangelia Sereti · 1 shared paper, 2018 · strength 0.08
   • Paper Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: emerging allies in the war on a devas… DOI 10.1016/j.jprot.2018.01.012↗
8. Dimitris Zacharoulis · 1 shared paper, 2018 · strength 0.08
   • Paper Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: emerging allies in the war on a devas… DOI 10.1016/j.jprot.2018.01.012↗
9. Konstantinos Vellios Kamposioras · 1 shared paper, 2018 · strength 0.08
   • Paper Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: emerging allies in the war on a devas… DOI 10.1016/j.jprot.2018.01.012↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.